OP-ED: FUNDING ROADBLOCKS CREATING DIGITAL HEALTH INEQUITY Beyond just clinical: Making the case for a pivot in reimbursement by Australian Government
With
Helen Souris,
CEO and Executive Director
Cardihab &
Board Member
Medical Technology Association of Australia (MTAA)
OP ED SEGMENT
Filmed in Sydney | June 2026
Helen Souris, CEO and Executive Director of Cardihab and Chair of the Digital Health Advisory Group at the Medical Technology Association of Australia (MTAA), highlights the significant gap in cardiac rehabilitation access across Australia. Despite the proven benefits of cardiac rehabilitation in improving survival, quality of life, and reducing hospital admissions, around 80% of eligible patients do not receive this care, with access rates even lower in regional and rural communities.
Cardihab was established as a digital health company originating from CSIRO research and has spent the past decade developing a digital therapeutic solution for cardiac rehabilitation.
Delivered through a clinically supervised software platform, the program enables patients to access rehabilitation remotely, removing barriers associated with travel and face-to-face attendance. The platform is registered with the Therapeutic Goods Administration (TGA) as a Class IIa medical device, reflecting its compliance with rigorous clinical and regulatory standards.
Over ten years, Cardihab has built a substantial evidence base, including randomised controlled trials and real-world studies. Independent research has demonstrated improvements in patient outcomes, quality of life, and cost-effectiveness, with the program outperforming traditional alternatives in most evaluated scenarios. As a result, the majority of private health insurers now support access to the platform, while statewide implementation has been achieved through partnerships such as the Tasmanian Health Service.
Despite these successes, Souris identifies funding as the primary barrier to broader adoption within the public health system. She argues that Australia already possesses the technology required to support the government’s digital health ambitions and that sustainable funding and reimbursement mechanisms are now needed to enable widespread access to evidence-based digital therapeutics and remote patient care solutions.
Source: Adapted from transcript
Media access credit: Medical Technology Association of Australia (MTAA)
Note: Op Ed segments are opinions and comments on policies. They should be watched for awareness purposes only, and do not necessarily reflect the views held by Australian Health Journal.
-
Study on digital tool for pharmacists in aged care
In March 2022, the Australia government announced $350 million of funding over 4 years to employ on-site pharmacists in residential aged care, starting July 2023. In April 2023, the government made changes to the proposed on-site pharmacists, where the new program will now be delivered by and through community pharmacies. Regardless of how the model will be implemented, the goal remains the same – to improve quality use of medicines and medicines safety for aged care residents.
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
